相关实验视频
Updated: Sep 12, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.0K
在危急病的老年患者中对药理性血栓预防的评估:多中心队列研究
Rahaf Alqahtani1, Khalid Al Sulaiman2, Ohoud Aljuhani3
1Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Heart & lung : the journal of critical care
|August 7, 2025
概括
埃诺沙巴林在重症老年人中显示出减少大出血的趋势,但与未分离的肝素相比,它并没有显著降低血栓形成率. 需要进一步的研究来证实这些发现用于静脉血栓塞栓症 (VTE) 预防.
科学领域:
- 关键护理医学 关键护理医学
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 进入重症监护室 (ICU) 的老年人面临着静脉血栓栓塞 (VTE) 的风险增加.
- 亲肠道抗凝药是预防重症患者静脉血栓炎的标准.
- 对老年ICU患者最佳VTE预防剂和剂量的证据有限.
研究的目的:
- 为了评估药物学VTE预防在危急病的老年患者的疗效和安全性.
- 在这个人群中,比较未分离的氨酸 (UFH) 与埃诺沙巴林用于VTE预防.
主要方法:
- 65岁及以上的ICU患者的多中心回顾性队列研究.
- 皮下UFH与Enoxaparin用于VTE预防的比较.
- 倾向性得分匹配 (2:1) 用于平衡患者的特征.
主要成果:
- 埃诺沙巴林组显示出较少重大出血事件的趋势 (2.9%对10.7%),但在统计学上不显著 (P=0.07).
- 两组之间在总体血栓形成率 (P=0.53) 或轻微出血 (P=0.11) 中没有发现显著差异.
- 埃诺沙巴林和UFH预防之间,死亡率和ICU并发症没有显著差异.
结论:
- 埃诺沙巴林可能会在重症老年人中减少大出血的趋势,这需要进一步调查.
- 目前的证据显示,埃诺沙巴林和UFH之间的VTE或出血率没有显著差异.
- 随机对照试验是必要的,以验证这些发现,并探索长期结果.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44
Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
Pulmonary Embolism III: Nursing Management
41
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
41
Anticoagulant Drugs: Low-Molecular-Weight Heparins
909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

